Orforglipron – Oral GLP-1 Receptor Agonist

Orforglipron (LY3502970) is Eli Lilly’s innovative oral, non-peptide GLP-1 receptor agonist, designed for the treatment of obesity and type 2 diabetes. Unlike injectable GLP-1 drugs, Orforglipron offers a once-daily oral option with strong efficacy in weight loss and glucose control. 

• Active ingredient: Orforglipron (small molecule GLP-1 agonist)
• Formulation: Oral tablet, once daily
• Half-life: 25–68 hours, enabling sustained activity
• Indications: Obesity, overweight management, type 2 diabetes
• Developer: Eli Lilly & Co.

• Duration: 26–36 weeks
• Weight Loss: Average 8.6% to 14.7% body weight reduction
• Glucose Control: HbA1c reduction up to 2.1%

• Participants: 559 type 2 diabetes patients
• Results:
  
  • Mean weight loss: ~7.9% (16 lbs) in highest dose group
  • HbA1c reduction: 1.3%–1.6%
  • Safety profile consistent with GLP-1 class

Orforglipron represents a breakthrough in oral obesity and diabetes treatment. With its convenient daily tablet form, robust clinical outcomes, and competitive safety profile, it may reshape the global GLP-1 therapy landscape. As Eli Lilly progresses toward regulatory approval, Orforglipron is positioned to become a key player in the next generation of weight management and metabolic therapies.